Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Acquired by Northern Trust Corp

Northern Trust Corp increased its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 19.6% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 878,860 shares of the biopharmaceutical company's stock after purchasing an additional 143,941 shares during the period. Northern Trust Corp owned approximately 0.68% of Alnylam Pharmaceuticals worth $206,805,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of ALNY. Tidal Investments LLC grew its holdings in shares of Alnylam Pharmaceuticals by 75.1% during the third quarter. Tidal Investments LLC now owns 20,544 shares of the biopharmaceutical company's stock worth $5,650,000 after purchasing an additional 8,811 shares during the last quarter. American Trust acquired a new stake in Alnylam Pharmaceuticals in the 3rd quarter valued at about $309,000. Versant Capital Management Inc raised its stake in shares of Alnylam Pharmaceuticals by 77.6% in the fourth quarter. Versant Capital Management Inc now owns 190 shares of the biopharmaceutical company's stock worth $45,000 after acquiring an additional 83 shares during the last quarter. Everence Capital Management Inc. acquired a new position in shares of Alnylam Pharmaceuticals during the fourth quarter worth approximately $593,000. Finally, Nordea Investment Management AB grew its stake in shares of Alnylam Pharmaceuticals by 6.7% during the fourth quarter. Nordea Investment Management AB now owns 10,188 shares of the biopharmaceutical company's stock valued at $2,417,000 after purchasing an additional 637 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company's stock.

Alnylam Pharmaceuticals Trading Down 0.7 %

Alnylam Pharmaceuticals stock traded down $1.99 during midday trading on Tuesday, hitting $271.56. 1,025,665 shares of the stock were exchanged, compared to its average volume of 874,469. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. The stock's 50-day simple moving average is $248.81 and its 200 day simple moving average is $254.55. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $144.73 and a fifty-two week high of $304.39. The stock has a market capitalization of $35.33 billion, a price-to-earnings ratio of -124.77 and a beta of 0.17.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.07). The company had revenue of $594.19 million during the quarter, compared to analysts' expectations of $584.32 million. During the same period last year, the firm earned ($0.16) earnings per share. The company's revenue was up 20.2% on a year-over-year basis. On average, equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CMO Pushkal Garg sold 1,548 shares of the firm's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $251.67, for a total transaction of $389,585.16. Following the transaction, the chief marketing officer now owns 11,989 shares of the company's stock, valued at approximately $3,017,271.63. This trade represents a 11.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Kevin Joseph Fitzgerald sold 663 shares of the business's stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $255.21, for a total value of $169,204.23. Following the completion of the sale, the executive vice president now directly owns 14,321 shares of the company's stock, valued at $3,654,862.41. The trade was a 4.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 7,392 shares of company stock worth $1,875,627. Company insiders own 1.50% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have commented on ALNY. Bank of America upped their target price on shares of Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the company a "buy" rating in a research report on Friday, March 21st. Scotiabank raised their price objective on Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the stock a "sector outperform" rating in a research note on Monday, March 31st. UBS Group boosted their price objective on shares of Alnylam Pharmaceuticals from $331.00 to $349.00 and gave the company a "buy" rating in a research report on Friday. Chardan Capital boosted their price target on Alnylam Pharmaceuticals from $300.00 to $325.00 and gave the company a "buy" rating in a report on Friday. Finally, StockNews.com downgraded Alnylam Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Wednesday, April 30th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and twenty-one have assigned a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $319.17.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.